Calreticulin is a B cell molecular target in some gastrointestinal malignancies

Clinical and Experimental Immunology

Volumn 160, Issue 2, 2010, Pages 215-222

  Pekarikova A ^a   Sanchez D ^a   Palova Jelinkova L ^a   Simsova M ^a   Benes Z ^b   Hoffmanova I ^b   Drastich, P ^c   Janatkova I ^c   Mothes, T ^d   Tlaskalova Hogenova H ^a   Tuckova L ^a  

^a INSTITUTE OF MICROBIOLOGY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Antigenic epitopes; Autoantibodies; Calreticulin; Hepatocellular carcinoma; Pancreatic adenocarcinoma

Indexed keywords

AUTOANTIBODY; CALRETICULIN; CALRETICULIN ANTIBODY; GLYCYLVALYLTHREONYLLYSYLALANYLALANYLGLUTAMYLLYSYLGLUTAMINYLMETHIONYLLYSYLASPARTIC ACID; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LYSYLGLYCYLGLUTAMYLTRYPTOPHANYLLYSYLPROLYLARGINYLGLUTAMINYLISOLEUCYLASPARTYLASPARAGINYLPROLINE; PEPTIDE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE ANTIBODY; UNCLASSIFIED DRUG; VALYLGLUTAMINYLPHENYLALANYLTHREONYLVALYLLYSYLHISTIDYLGLUTAMYLGLUTAMINYLASPARTYLISOLEUCYLASPARTIC ACID;

ADULT; AGED; ANTIBODY SPECIFICITY; ARTICLE; CHRONIC PANCREATITIS; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN TARGETING; SENSITIVITY AND SPECIFICITY; SEROLOGY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, NEOPLASM; ANTIBODY SPECIFICITY; AUTOANTIBODIES; AUTOANTIGENS; B-LYMPHOCYTES; CALRETICULIN; CARCINOMA, HEPATOCELLULAR; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; GALLBLADDER NEOPLASMS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PANCREATITIS; YOUNG ADULT;

EID: 77950653586     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2009.04085.x     Document Type: Article

References (32)

1. Obeid M, Tesniere A, Ghiringhelli F et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007 13 : 54 61. (Pubitemid 46067386)
2. Basu S, Srivastava PK. Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity. J Exp Med 1999 189 : 797 802.
3. Clarke C, Smyth MJ. Calreticulin exposure increases cancer immunogenicity. Nat Biotechnol 2007 25 : 192 193.
4. Obeid M, Tesniere A, Panaretakis T et al. Ecto-calreticulin in immunogenic chemotherapy. Immunol Rev 2007 220 : 22 34.
5. Eggleton P, Llewellyn DH. Pathophysiological roles of calreticulin in autoimmune disease. Scand J Immunol 1999 49 : 466 473.
6. Staikou EV, Routsias JG, Makri AA et al. Calreticulin binds preferentially with B cell linear epitopes of Ro60 kD autoantigen, enhancing recognition by anti-Ro60 kD autoantibodies. Clin Exp Immunol 2003 134 : 143 150.
7. Michalak M, Groenendyk J, Szabo E et al. Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. Biochem J 2009 417 : 651 666.
8. Tan EM. Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Invest 2001 108 : 1411 1415.
9. Zhang JY, Casiano CA, Peng XX et al. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 2003 12 : 136 143.
10. Fernández Madrid F. Autoantibodies in breast cancer sera: candidate biomarkers and reporters of tumorigenesis. Cancer Lett 2005 230 : 187 198.
11. Conroy SE, Sasieni PD, Fentiman I et al. Autoantibodies to the 90kDa heat shock protein and poor survival in breast cancer. Eur J Cancer 1998 34 : 942 943.
12. Bei R, Masuelli L, Palumbo C, Modesti M, Modesti A. A common repertoire of autoantibodies is shared by cancer and autoimmune disease patients: inflammation in their induction and impact on tumor growth. Cancer Lett 2009 281 : 8 23.
13. Desmetz C, Bibeau F, Boissiere F et al. Proteomics-based identification of HSP60 as a tumor-associated antigen in early stage breast cancer and ductal carcinoma in situ. J Proteome Res 2008 7 : 3830 3837.
14. Konstadoulakis MM, Syrigos KN, Leandros M, Charalabopoulos A, Monouras A, Golematis BC. Autoantibodies in the serum of patients with gastric cancer: their prognostic importance. Hybridoma 1998 17 : 431 435.
15. Ward RL, Hawkins NJ, Coomber D, Disis ML. Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer. Hum Immunol 1999 60 : 510 515.
16. Albanopoulos K, Armakolas A, Konstadoulakis MM et al. Prognostic significance of circulating antibodies against carcinoembryonic antigen (anti-CEA) in patients with colon cancer. Am J Gastroenterol 2000 95 : 1056 1061.
17. Yagihashi A, Asanuma K, Tsuji N et al. Detection of anti-livin antibody in gastrointestinal cancer patients. Clin Chem 2003 49 : 1206 1208.
18. Saleh J, Kreissler-Haag D, Montenarh M. p53 autoantibodies from patients with colorectal cancer recognize common epitopes in the N- or C-terminus of p53. Int J Oncol 2004 25 : 1149 1155.
19. Megliorino R, Shi FD, Peng XX et al. Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection. Cancer Detect Prev 2005 29 : 241 248.
20. Saif MW, Zalonis A, Syrigos K. The clinical significance of autoantibodies in gastrointestinal malignancies: an overview. Exp Opin Biol Ther 2007 7 : 493 507.
21. Vougas K, Gaitanarou E, Marinos E, Kittas C, Voloudakis-Baltatzis IE. Two-dimensional electrophoresis and immunohistochemical study of calreticulin in colorectal adenocarcinoma and mirror biopsies. J BUON 2008 13 : 101 107.
22. Erić A, Juranić Z, Milovanović Z et al. Effects of humoral immunity and calreticulin overexpression on postoperative course in breast cancer. Pathol Oncol Res 2009 15 : 89 90.
23. Yoon GS, Lee H, Jung Y et al. Nuclear matrix of calreticulin in hepatocellular carcinoma. Cancer Res 2000 60 : 1117 1120.
24. Sánchez D, Palová-Jelínková L, Felsberg J et al. Anti-calreticulin immunoglobulin A (IgA) antibodies in refractory coeliac disease. Clin Exp Immunol 2008 153 : 351 359.
25. Sánchez D, Tučková L, Mothes T et al. Epitopes of calreticulin recognised by IgA autoantibodies from patients with hepatic and coeliac disease. J Autoimmun 2003 21 : 383 392.
26. Laemmli UK, Favre M. Maturation of the head of bacteriophage T4. I. DNA packaging events. J Mol Biol 1973 80 : 575 599.
27. Verma A, Guha S, Diagaradjane P et al. Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res 2008 14 : 2476 2483.
28. Sánchez D, Tučková L, Šebo P et al. Occurrence of IgA and IgG autoantibodies to calreticulin in coeliac disease and various autoimmune diseases. J Autoimmun 2000 15 : 441 449.
29. Le Naour F, Brichory F, Misek DE, Bréchot C, Hanash SM, Beretta L. A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis. Mol Cell Proteomics 2002 3 : 197 203.
30. Hong SH, Misek DE, Wang H et al. An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer. Cancer Res 2004 64 : 5504 5510.
31. Tan TT, Coussens LM. Humoral immunity, inflammation and cancer. Curr Opin Immunol 2007 19 : 209 216.
32. Ellyard JI, Simson L, Parish CR. Th2-mediated anti-tumour immunity: friend or foe? Tissue Antigens 2007 70 : 1 11.